# Guangzhou Lupeng Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangzhou-lupeng-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Total disclosed funding: $24M
- Latest round: Series A (Jun 23, 2020)
- Investors on record: 4

## About

Based in Guangzhou, China and established in 2018, Guangzhou Lupeng Pharmaceutical operates as a pharmaceutical company which focuses on molecular science. In July 2021, the company raised series Pre-B funding from investor.

The company's main business is self-developed innovative drug for the treatment of major diseases such as tumor, hepatitis B, autoimmunity, etc. The company's main product is LP-108 which is a selective BCL-2 (B-cell lymphoma-2) inhibitor.

The company plans to use the series Pre-B funding to clinical research of selective BCL-2 (B-cell lymphoma-2) inhibitor.

## Funding rounds

- Series A, Jun 23, 2020, $24M — Lilly Asia Ventures, Kaitai Capital, TF Capital, FC Capital - China
- Seed, Jun 27, 2018 — Kaitai Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed, Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- TF Capital — Series A
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series A